Craft

Haemonetics

Stock Price

$73.1

2024-10-29

Market Capitalization

$3.7 B

2024-10-29

Revenue

$1.3 B

FY, 2024

Haemonetics Summary

Company Summary

Overview
Haemonetics is a provider of medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The Plasma segment offers plasma collection devices and disposables, plasma donor management software, and anticoagulant and saline. The Blood Center segment delivers blood collection and processing devices and disposables for red cells, platelets, and whole blood. The Hospital segment provides devices and methodologies for measuring coagulation characteristics of blood, vascular closure devices, specialized blood cell processing systems and disposables, surgical blood salvage systems, and blood transfusion management software.
Type
Public
Status
Active
Founded
1971
HQ
Boston, MA, US | view all locations
Website
https://www.haemonetics.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Christopher Simon

    Christopher Simon, President, Chief Executive Officer

  • James C. D'Arecca

    James C. D'Arecca, Executive Vice President, Chief Financial Officer

  • Jan Hartmann

    Jan Hartmann, Senior Vice President, Chief Medical Officer

  • Anila Lingamneni

    Anila Lingamneni, Executive Vice President, Chief Technology Officer

Operating MetricsView all

Facility Space, sq. ft.

1.4M
20.4%

FY, 2023

Facility Space Leased, sq. ft.

885.4K
40.8%

FY, 2023

Facility Space Owned, sq. ft.

543.4K
80.9%

FY, 2023

LocationsView all

26 locations detected

  • Boston, MA HQ

    United States

    125 Summer St

  • Covina, CA

    United States

    1630 Industrial Park Street

  • Draper, UT

    United States

    12046 Lone Peak Parkway

  • Findlay Township, PA

    United States

    1300 Clifford Ball Drive

  • Mt. Juliet, TN

    United States

    549 Aldi Boulevard

  • Salt Lake City, UT

    United States

    1555 South Gramercy Road, Suite #500

and 20 others

Haemonetics Financials

Summary Financials

Revenue (Q3, 2025)
$348.5M
Gross profit (Q3, 2025)
$193.5M
Net income (Q3, 2025)
$37.5M
Cash (Q3, 2025)
$320.8M
EBIT (Q3, 2025)
$59.0M
Enterprise value
$4.6B

Footer menu